<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000966</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 156</org_study_id>
    <nct_id>NCT00000966</nct_id>
  </id_info>
  <brief_title>A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS</brief_title>
  <official_title>A Dose-Escalation, Phase I/II Study of Oral Azithromycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness and toxicity of oral azithromycin and pyrimethamine as acute
      therapy for toxoplasmic encephalitis in AIDS patients. To assess the toxicity and
      effectiveness of azithromycin alone as maintenance therapy.

      Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous
      system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard
      treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus,
      alternative treatments are needed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Encephalitis caused by Toxoplasma gondii is the most frequent cause of focal central nervous
      system infection in patients with AIDS. Untreated, the encephalitis is fatal. Standard
      treatment for toxoplasmic encephalitis is associated with serious adverse effects. Thus,
      alternative treatments are needed.

      Patients with toxoplasmosis are given azithromycin at doses starting at the lowest dose for
      the first cohort, an intermediate dose for the second cohort, and a higher dose for the third
      cohort. Subsequent cohorts may receive azithromycin in increased dosage, if needed to
      determine the MTD. All patients also receive pyrimethamine. Folinic acid is also provided for
      as long as patients receive pyrimethamine. Patients are evaluated for clinical response to
      treatment at days 3, 7, and 14, and weekly for 6 weeks. Maintenance treatment with
      azithromycin continues for an additional 24 weeks. Patients who complete the study period
      without relapse or significant toxicity are offered continued therapy by the drug company and
      are followed for survival and relapse on a monthly basis for 1 year. After the MTD is
      determined, a subsequent cohort may be added for special studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>45</enrollment>
  <condition>Toxoplasmosis, Cerebral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP).

          -  Allowed during maintenance period (weeks 7 - 24):

          -  Zidovudine and other antiretrovirals available through treatment IND mechanisms,
             ganciclovir, and maintenance doses of amphotericin (other investigational therapies
             require permission from the study chair), steroids for the treatment of acute PCP.

          -  Isoniazid (INH) only for patients already on INH.

        Patients must have the following:

          -  HIV infection or belong to high-risk group. Presumptive or definite diagnosis of
             toxoplasmic encephalitis.

          -  Each patient, or his/her appropriate family member, or legal designee must be able to
             understand and sign a written informed consent, in accordance with the local practices
             at each site.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or
             tissue.

          -  Coma.

          -  More than 72 hours of treatment for current episode of toxoplasmic encephalitis prior
             to study entry.

          -  Central nervous system (CNS) lymphoma.

          -  Cerebral Kaposi's sarcoma.

          -  Active hepatitis or clinical jaundice.

          -  History of serious hypersensitivity or intolerance to any of the study drugs.

          -  Serum or cerebrospinal fluid (CSF) positive for cryptococcus antigen or culture.

          -  Malignancies requiring use of cytotoxic chemotherapy.

          -  Inability to take oral therapy reliably.

          -  Malabsorption syndrome.

        Concurrent Medication:

        Excluded:

          -  Opportunistic infection requiring either acute treatment or maintenance therapy with
             azithromycin, erythromycin or other macrolides, sulfonamides, amphotericin, dapsone,
             ganciclovir, antifolates, and other investigational agents except erythropoietin. For
             first 6 weeks of treatment, patients may not receive treatment with erythromycin (or
             other macrolides), sulfonamides, immunomodulators with the exception of alpha
             interferon, lymphocyte replacement, cytotoxic chemotherapy, dapsone, ganciclovir,
             rifampicin, coumadin, antiretrovirals, and investigational agents other than
             erythropoietin.

        Patients with the following are excluded:

          -  Negative HIV antibodies by a federally licensed ELISA, unless there is documentation
             of a previously positive HIV culture or p24 antigen.

          -  Infections of the central nervous system.

          -  Malignancies requiring the use of cytotoxic chemotherapy.

          -  Any medical or social condition that, in the opinion of the investigator, would
             adversely affect participation and/or compliance in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luft B</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Remington J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County - USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Massachusetts Med Ctr</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Municipal Hosp Ctr/Jacobi Med Ctr</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Med Ctr / Bronx Municipal Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronx Veterans Administration / Mount Sinai Hosp</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nassau County Med Ctr</name>
      <address>
        <city>East Meadow</city>
        <state>New York</state>
        <zip>11554</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Stony Brook</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>117948153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Saba J, Morlat P, Raffi F, Hazebroucq V, Joly V, Leport C, Vild√© JL. Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS. Eur J Clin Microbiol Infect Dis. 1993 Nov;12(11):853-6.</citation>
    <PMID>8112357</PMID>
  </reference>
  <reference>
    <citation>. Kamarulzaman A, Hoy J. Effect of folinic acid on haematological toxicity during treatment of cerebral toxoplasmosis in patients with AIDS. Annu Conf Australas Soc HIV Med. 1995 Nov 16-19;7:68 (abstract no 68)</citation>
  </reference>
  <reference>
    <citation>Jacobson JM, Hafner R, Remington J, Farthing C, Holden-Wiltse J, Bosler EM, Harris C, Jayaweera DT, Roque C, Luft BJ; ACTG 156 Study Team. Dose-escalation, phase I/II study of azithromycin and pyrimethamine for the treatment of toxoplasmic encephalitis in AIDS. AIDS. 2001 Mar 30;15(5):583-9.</citation>
    <PMID>11316995</PMID>
  </reference>
  <verification_date>October 1994</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>August 25, 2008</last_update_submitted>
  <last_update_submitted_qc>August 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Toxoplasma</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Encephalitis</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Azithromycin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

